Full Text View
Tabular View
No Study Results Posted
Related Studies
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma (GRAAL2)
This study has been terminated.
( due to poor enrollment )
Study NCT00664144   Information provided by Sanofi-Aventis
First Received: April 18, 2008   Last Updated: March 27, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hyperuricemia
Additional conditions recognized in this trial
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
Rasburicase (SR29142)
Additional drug interventions recognized in this trial
Rasburicase
More general drug interventions related to this trial
Antirheumatic Agents
Gout Suppressants
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Sanofi-Aventis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services